HomeMEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES

HAART 200 Aortic Annuloplasty Device: 1st European Commercialization Implantation Reported

HAART 200 Aortic Annuloplasty Device

HAART 200 Aortic Annuloplasty Device

HAART 200 Aortic Annuloplasty Device first commercial implantation was  performed on Monday, August 2nd by Professor Marek Jasinski, Chief of Cardiac Surgery at Wroclaw Medical University (Wroclaw, Poland). BioStable Science & Engineering announced the news today.

Additional procedures were completed on Thursday, August 5th by Professor Marek Deja, Chief of Cardiac Surgery at the Medical University of Silesia (Katowice, Poland). These two respected heart centers were the first selected to receive the device as part of the limited European commercial launch of the technology announced by the company in April.

Professor Jasinski commented, “The HAART 200 Aortic Annuloplasty Device is a great addition to our aortic valve repair tool kit providing a new option for the most common congenital heart defect, bicuspid aortic valve disease. Our experience with the HAART 300 Aortic Annuloplasty Devices in trileaflet aortic valve repair has shown us how the devices simplify aortic valve repair and at the same time provide durable annuloplasty. This allows us to expand the benefits of valve repair to more patients. The availability of the HAART 200 Device is critically important because patients with bicuspid aortic valve disease are younger, multiplying the benefits of valve repair vs. replacement.”

Although compelling long-term clinical data suggest that almost all bicuspid aortic valves should be repaired[1], current repair techniques are complex and not widely adopted. The HAART 200 Device simplifies bicuspid aortic valve repair by stabilizing the annulus and remodeling the valve into a symmetric, 180-degree leaflet orientation, eliminating the need for extensive dissection of the aortic root, and facilitating leaflet repair.

John Wheeler, President and CEO, concluded by saying, “BioStable is very pleased to initiate commercialization of the HAART 200 Aortic Annuloplasty Device alongside the HAART 300 Devices. With the commercial availability of the HAART 200 and HAART 300 Aortic Annuloplasty Devices, BioStable can offer surgeons within the European a comprehensive portfolio of aortic valve repair solutions that address all forms of aortic valve insufficiency.”

OTHER

 

SourceBioStable Science & Engineering
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society 2023 Annual Meeting

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."

Research Team at UNC Validates PixCell Medical’s HemoScreen as Game-Changer for Clozapine Monitoring in Psychiatry

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).

Inspira Technologies Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

Medical Device News Magazine

Editorial Contact: mdnewsmagazine@infomeddnews.com

Medical Device News Magazine can help promote your medical devices, technologies, products or services. Advertising Contact: advmdn@infomeddnews.com

Telephone

© Copyright 2022 Medical Device News Magazine, is a division of PTM Healthcare Marketing, Inc

By using this website you agree to accept Medical Device News Magazine Privacy Policy